Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Livio Pagano, Jon Salmanton-García, Francesco Marchesi, Ola Blennow, Maria Gomes da Silva, Andreas Glenthøj, Jaap A van Doesum, Yavuz M Bilgin, Alberto Lopez-Garcia, Federico Itri, Raquel Nunes Rodrigues, Barbora Weinbergerová, Francesca Farina, Giulia Dragonetti, Caroline Berg Venemyr, Jens Van Praet, Ozren Jaksic, Toni Valkovic, Iker Falces-Romero, Sonia Martin-PerezMoraima Jiménez, Julio Davila-Valls, Martin Schonlein, Emanuele Ammatuna, Stef Meers, Mario Delia, Zlate Stojanoski, Anna Nordlander, Tobias Lahmer, László Imre Pinczés, Caterina Buquicchio, Klára Piukovics, Irati Ormazabal-Velez, Nicola Stefano Fracchiolla, Michail Samarkos, Gustavo-Adolfo Mendez, José-Ángel Hernández-Rivas, Ildefonso Espigado, Martin Cernan, Verena Petzer, Sylvain Lamure, Roberta Di Blasi, Joyce Marques de Almeida, Michelina Dargenio, Monika Maria Biernat, Mariarita Sciumè, Cristina de Ramón, Nick Alexander De Jonge, Josip Batinic, Avinash Aujayeb, Monia Marchetti, Guillemette Fouquet, Noemi Fernández Escalada, Giovanni Paolo Maria Zambrotta, Maria Vittoria Sacchi, Anna Guidetti, Fatih Demirken, Lucia Prezioso, Zdenek Racil, Marcio Nucci, Miloš Mladenovic, Raphaël Lievin, Michaela Hanakova, Stefanie K Grafe, Uluhan Sili, Marina Machado, Chiara Cattaneo, Tatjana Adzic-Vukicevic, Luisa Verga, Jorge Labrador, Laman Rahimli, Matteo Bonanni, Francesco Passamonti, Antonio Pagliuca, Paolo Corradini, Martin Hoenigl, Philipp Koehler, Alessandro Busca, Oliver A Cornely

43 Citationer (Scopus)

Abstract

Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received ≤2 vaccine doses before COVID-19 (1419, 91%), mostly mRNA-based (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P < .001), active HM (P < .001), and severe and critical COVID-19 (P = .007 and P < .001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P < .001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P < .001) or combined with antivirals (P = .009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.

OriginalsprogEngelsk
TidsskriftBlood
Vol/bind140
Udgave nummer26
Sider (fra-til)2773-2787
Antal sider15
ISSN0006-4971
DOI
StatusUdgivet - 29 dec. 2022

Fingeraftryk

Dyk ned i forskningsemnerne om 'Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey'. Sammen danner de et unikt fingeraftryk.

Citationsformater